Sham injections + Ranibizumab 0.5 mg
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Visual Impairment Due to Diabetic Macular Edema
Conditions
Visual Impairment Due to Diabetic Macular Edema
Trial Timeline
Jun 1, 2010 → Jul 1, 2011
NCT ID
NCT01131585About Sham injections + Ranibizumab 0.5 mg
Sham injections + Ranibizumab 0.5 mg is a phase 3 stage product being developed by Novartis for Visual Impairment Due to Diabetic Macular Edema. The current trial status is terminated. This product is registered under clinical trial identifier NCT01131585. Target conditions include Visual Impairment Due to Diabetic Macular Edema.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01131585 | Phase 3 | Terminated |
Competing Products
13 competing products in Visual Impairment Due to Diabetic Macular Edema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 77 |
| Blink® Tears eye drops + Investigational lipid eye drops | Johnson & Johnson | Phase 1 | 33 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 77 |
| Ranibizumab + Aflibercept | Novartis | Approved | 85 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 23 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 30 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 20 |